Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling
T W. Grunt, G L. Mariani - Current cancer drug targets, 2013 - benthamdirect.com
Breast cancer is one of the most prevalent and devastating malignant diseases in women
worldwide. Fortunately, while breast cancer incidence is still increasing, its death rate is …
worldwide. Fortunately, while breast cancer incidence is still increasing, its death rate is …
Targeting PI3K/AKT/mTOR signaling pathway in breast cancer
Simple Summary PI3K signaling pathway plays an essential role in many cellular processes
and is frequently altered in breast cancer, leading to increased tumor growth and reduced …
and is frequently altered in breast cancer, leading to increased tumor growth and reduced …
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
E Paplomata, R O'Regan - Therapeutic advances in medical …, 2014 - journals.sagepub.com
The phosphoinositide 3 kinase (PI3K)/Akt/mammalian (or mechanistic) target of rapamycin
(mTOR) pathway is a complicated intracellular pathway, which leads to cell growth and …
(mTOR) pathway is a complicated intracellular pathway, which leads to cell growth and …
Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients
SE Ghayad, PA Cohen - Recent patents on anti-cancer drug …, 2010 - ingentaconnect.com
Aberrant activation of the PI3K/Akt/mTOR pathway is found in many types of cancer and thus
plays a major role in breast cancer cell proliferation and anti-cancer drug resistance. The …
plays a major role in breast cancer cell proliferation and anti-cancer drug resistance. The …
Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions
JMS Bartlett - Clinical breast cancer, 2010 - Elsevier
Abstract The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) pathway regulates a broad spectrum of physiologic and pathologic processes. In …
(mTOR) pathway regulates a broad spectrum of physiologic and pathologic processes. In …
The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts
M McKenna, S McGarrigle, GP Pidgeon - Biochimica et Biophysica Acta …, 2018 - Elsevier
Abstract The PI3K/Akt/mTOR pathway plays a role in various oncogenic processes in breast
cancer and key pathway aberrations have been identified which drive the different molecular …
cancer and key pathway aberrations have been identified which drive the different molecular …
Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer
Abstract The PI3K/Akt/mTOR (phosphatidylinositol 3 kinase/Akt/mammalian target of
rapamycin) signalling pathway is an established driver of oncogenic activity in human …
rapamycin) signalling pathway is an established driver of oncogenic activity in human …
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
N Dey, P De, B Leyland-Jones - Pharmacology & therapeutics, 2017 - Elsevier
Breast cancer (BC) is the most common women cancer and second most common cause of
cancer death in women. A woman living in the United States has 12.3% lifetime risk of being …
cancer death in women. A woman living in the United States has 12.3% lifetime risk of being …
Signal transduction pathways in breast cancer: the important role of PI3K/Akt/mTOR
MA Ortega, O Fraile-Martínez, Á Asúnsolo… - Journal of …, 2020 - Wiley Online Library
Breast cancer is the cancer with the highest prevalence in women and is the number‐one
cause of cancer mortality worldwide. Cell transduction is a fundamental process in the …
cause of cancer mortality worldwide. Cell transduction is a fundamental process in the …
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT
NA O'Brien, K McDonald, L Tong, E von Euw… - Clinical Cancer …, 2014 - AACR
Abstract Purpose: Altered PI3K/mTOR signaling is implicated in the pathogenesis of a
number of breast cancers, including those resistant to hormonal and HER2-targeted …
number of breast cancers, including those resistant to hormonal and HER2-targeted …